论文部分内容阅读
Monoclonal antibodies have been started to use in cardiovascular pathologies both diagnostics measurement of cardiac troponin enzymes, and treatment.After infarction of myocardium or cardiovascular by-pass operation; inflammation especially complement activation triggered and with atherosclerotic process mortality and morbidity increased.Pexelizumab, which inhibits C-5 complement activation, is one of humanized monoclonal antibodies that used in cardiovascular system diseases, maintaining both ST elevation myocardial infarction and coroner artery bypass surgery.